Saint Agnes Medical Center Oncology Symposium October 15, 2011 Neoadjuvant, Adjuvant and Palliative Management Marshall Flam, MD Hematology, Oncology Medical.

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

Advances and Emerging Therapy for Lung Cancer

Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉財團法人台灣癌症臨床研究發展基金會.

Discussion Pancreatic Cancer Abstracts 145, LBA146, 147, & LBA148

Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.

Rectal Cancer: Advanced Technologies Chris Willett, M.D. Department of Radiation Oncology Duke University Medical Center Durham, NC.

Our bold approach to life-changing medicines

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

CHEMOTHERAPY AND BLADDER CANCER Walter Stadler, MD, FACP University of Chicago.

Management of Pancreato- biliary Malignancy: Medical Oncology Perspective Robert A. Wolff, MD Professor of Medicine Department of GI Medical Oncology.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

NSABP PROTOCOL C-10: RESULTS A Phase II Trial of 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) Plus Bevacizumab for Patients with Unresectable.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Drug Treatment of Metastatic Breast Cancer

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.

Intergroup trial CALGB 80101

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Schwartz 44 yo woman with 4 mo hx of abdominal pain –Imaging = pancreatic.

Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

Patterns of Care in Medical Oncology Adjuvant Systemic Therapy for Colon Cancer.

Is surgical resection of an asymptomatic primary colorectal tumor beneficial for patients with incurable Stage IV disease? A Phase II Trial of 5-Fluorouracil,

The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.

Margaret Tempero Professor of Medicine University of California, San Francisco Therapeutic Landscapes In Pancreatic Cancer.

Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:

Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.

Gastric Cancer Gidon Almogy MD Department of General Surgery Hadassah University Hospital.

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

Pancreatic cancer chemotherapy Jarosław Reguła M.D. Department of Gastroenterology, Institute of Oncology, Warsaw, Poland.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Phase I/II Trial of Docetaxel plus Oxaliplatin and 5-Fluorouracil (D-FOX) in Patients with Untreated, Advanced Gastric or Gastroesophageal Cancer Jaffer.

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.

Best of ASCO – Colorectal & Pancreatic Cancers Best of ASCO Colorectal & Pancreatic Cancers Ali Shamseddine, MD Professor of Medicine Head of Hematology/Oncology.

Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.

ECCO ESMO 2011 GI Cancer Updates TAS102 and BSC vs. Placebo and BSC Reviewer: Dr. Scott Berry Date posted: October 2011.

C.P. Belani 1, D.M. Waterhouse 2, H.H. Ghazal 3, S. Ramalingam 4, J.M. Waples 5, R.E. Bordoni 6, G.A. Reznikoff 7, C.P. Curran 8, R. H. Greenberg 9 1 Penn.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,

Pre-Operative Therapy for Borderline Resectable Pancreatic Cancer: The Potential Role of Chemotherapy Robert A. Wolff, M.D. Associate Professor of Medicine.

Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic.

Dr Marco Matos Medical Oncologist Gold Coast Cancer Care, Gold Coast University Hospital and, Pacific Private Oncology Group.

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.

Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study Atul Sharma, Amit Dutt Dwary, Bidhu.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

What is the optimal pre-op therapy for esophagus and GE junction cancers?

Jordan Berlin Co-Director, GI Oncology Program

Adjuvant Radiation is Required for Gastric Cancer

Baselga J et al. SABCS 2009;Abstract 45.

Treatment of Locally Advanced Pancreatic Cancer

Neoadjuvant Adjuvant Curative Palliative

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.

Presentation transcript:

Saint Agnes Medical Center Oncology Symposium October 15, 2011 Neoadjuvant, Adjuvant and Palliative Management Marshall Flam, MD Hematology, Oncology Medical Group

Age Specific Incidence Rates of Pancreas Cancer, in California, by Race, Courtesy of Paul Mills, PhD, MPH

Stage at Diagnoses of PAC Stage at DX% of Patients5 Yr. Survival Distant Metastases502% Locally Advanced Un-resectable307% Curative Resection of Operated50 (10)20% Metastases Found at Surgery Un-resectable50 (10)

SINGLE AGENT CHEMOTHERAPY

Overall Survival: Gemcitabine vs 5-FU

Fixed Dose Rate vs. Standard Rate

Toxicity Summary Grade 3 and 4 Toxicities (% of Patients) Toxicity per Patient FDRStandard Anemia Nausea/vomiting Thrombocytopenia Neutropenia Leukopenia ALT Diarrhea Abbreviation: FDR, fixed dose rate.

Assessment of Clinical Benefit PAIN Performance Status STABLE In both Parameters WEIGHT Responder Improvement in both Parameters. Stable in one parameter, Improvement in The other parameter Non-responder Worsening in either Parameter Analgesic Consumption Pain Intensity Responder > 7% Increase in body weight Responder Stable or decreased weight

COMBINATION CHEMOTHERAPY

Phase III Trials of Chemotherapy in Advanced Pancreatic Cancer RegimenOS (mos)5FU OS (mos)P ValueRR (%)5FU RR % Gemcitabine + 5FU Gemcitabine + Irinotecan Gemcitabine + Cisplatin Gemcitabine + Oxaliplatin Gemcitabine + Premetrexed Capecitabine + Gemcitabine

EGOC Trail: Survival – Gemcitabine vs GEMOX

French Trial: Survival Gemcitabine vs GEMOX

Objective Responses in the Intention-to-Treat Population

Progression-free Survival

Overall Survival

TARGETED THERAPIES

Summary of the CAN-NCIC PA.3 Phase III Trial Gemcitabine +Erlotinib vs Gemcitabine Alone in Advanced Pancreatic Cancer Gemcitabine + Erlotinib Gemcitabine Alone Hazard Ratio P Value No. of Patients Response Rate 8.6%8.0% Median Survival 6.24 mos 5.91 mos Yr. Survival Rate 23%17% Progression-Free Survival 3.75 mos 3.55 mos Data from Moore et al. 23,24

Phase III Trial of Bevacizumba + Gemcitabine in Patients with Advanced Pancreatic Cancer: Median Overall and Progression-Free Survival Gemcitabine + Bevacizumab Gemcitabine + Placebo P ValueHazard Ratio Median Overall Survival 5.7 mos 6.0 mos (95% CI) (4.9, 6.5)(5.0, 6.9) Progression-Free Survival 4.8 mos 4.3 mos (95% CI) (4.3, 5.7)(3.8, 5.6) Data from Kindler et al. 11

SECOND LINE THERAPIES

Treatment RegimenNo. of patients Metastatic Disease (%) RR (%) a DCR (%) a PFS/TTP (months) OS (months) Oxa/5-FU CI/LV vs. BSC 14 46NA OFF: 5.25 BSC: 2.5 OFF: 10 BSC: 8.5 Oxa/5-FU CI/LV vs. 5-FU CI/LV 36, (OFF:77; FF91) OFF: 85.5 FF: 89.2 NA OFF: 3.25 FF: 2.25 OFF: 6.5 FF: 3.25 Oxa/5-FU CI/LV FOLFOX Modified FOLFOX(a) vs. modified FOLFIRI.3(b) 30 (a) 30 (b) 30 NA (a) 20 (b) 28 (a) 1.4 (b) 1.9 (a) 4 (b) 4 Oxa/5-FU CI Oxa + Gem Oxa + Cap 34 39NA323NA5.8 Oxa + Cap Oxa + irinotecan Oxa + pemetrexed 38 16NA NA Oxa + ralitrexed L -Cisplatin + Gem NA4.0 Cisplatin + irinotecan + Gem + 5-FU + LV Cisplatin + S NA 9.0 Cap + Gem + docetaxel NA11.2 Mitomycin + docetaxel + Irinotecan Irinotecan + ralitrexed a Intention-to-treat analysis. b KPS % Clinical Trials Investigating second-line combination chemotherapy in gemcitabine- pretreated patients with advanced pancreatic cancer

CONKO 003

Phase II trial of capecitabine + erlotinib in gemcitabine-refractory advanced pancreatic cancer

ADJUVANT THERAPY FOLLOWING RESECTION OF PAC

Key Trials of Adjuvant Therapy in Resectable Pancreatic Cancer TrialRegimen # of Patients Median Survival (mos) GITSG (1985) 5FU + 40GY XRT2120 Surgery Only2211 GITSG (1987) 5FU + 40GY XRT3018 EORTC (1999) 5FU + 40GY XRT Surgery Only ESGCP (2004) Chemoradiotherapy ESGCP (2004) No Chemoradiotherapy Maintenance Chemotherapy No Maintenance Chemotherapy RTOG (2006) 5FU Gy Gemcitabine + 5FU Gy * CONKO-001 (2007) Gemcitabine Surgery Only * Statistically Significant

NEO-ADJUVANT (PRE-OPERATIVE) THERAPY

Advantages Pre-operative Chemo radiation over Post-operative Chemo radiation More effective chemotherapy delivery with an intact blood supply Avoidance of hypoxia related chemo radiation resistance Avoidance of late radiation toxicity by surgical removal of irradiated duodenum and use of unirradiated jejunum use in reconstruction Immediate use of systemic therapy for a disease that is systemic at diagnosis in the majority of patients Improved patient selection for pancreatic surgery Pancreatic surgery is safer following chemo radiation due to reduced risk of pancreatic anastomotic leak due to pancreatic fibrosis Timely access to therapy. No delays due to post-operative recovery complications Increases R0 (complete) resection rates in patients with borderline resectable tumors

Operability Classification of Localized PAC based on high-quality cross-sectional imaging Resectable Borderline Resectable Locally Advanced Metastatic

Selected Trials of Neoadjuvant Chemoradiation for Patients with Potentially Resectable Pancreatic Cancer AuthorEvaluable Patients ResectedEBRT Dose (Gy) Chemotherapy Regimen Median Survival All Patients (Mo) Median Survival Resected Patients (Mo) Evans et al. (119)2817 (61%) IORTCI 5-FUNA18 Hoffman et al. (121)5324 (45%)50.4Bolus 5-FU Pisters et al. ( (57%)30 + IORTPVI 5-FU725 White et al.53 resectable28 (53%)45PVI 5-FUNR Moutardier et al (261)1915 (79%)30 or 45Bolus 5-FU + CDDP 2030 Arnoletti et al (262)2614 (54%)59.45-FU and/or MMC or Gem NA34 Pisters et al. (123)3520 (57%)30 and 10 IORTPaclitaxel1219 Wolff et al. (125)8664 (75%)30Gem2236 Magnin et al. (263)3219 (59)%30 or 45PVI 5-FU + CDDP1630 Talamonti et al. (126)2017 (85%)36 GyGemNA

Kaplan-Meier curves compare overall survival in patients according to timing of systemic therapy. MS indicate medial survival.

Kaplan Meier curves compare overall survival in patients with extra pancreatic disease (ie, T3 or T4 Disease) according to timing of sytematic therapy. MS indicates median survival.

Add Title

Need Title Survival adjusted for age, sex, and comorbidity for patients receiving treatment versus untreated patients.

Need Title Kaplan-Meier overall survival curves in patients with good Karnofsky performance score (90 to 100). Gem, gemcitabine; GemCap, Gemcitabine plus capecitabine.